InsiderTrades.com logo
JD Vance Predicts: Wall Street vs. Trump & Your Money
From Priority Gold   |   Ad
Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.
Get your free guide NOW before it's too late.

SPL Insider Trading

Insider Ownership Percentage: 12.97%
Insider Buying (Last 12 Months): A$273,960.30
Insider Selling (Last 12 Months): A$0.00

Starpharma Insider Trading History Chart

This chart shows the insider buying and selling history at Starpharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Starpharma Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET

This chart shows the closing price history over time for SPL up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
When it comes to NVDA… “acceleration cycles” are the key
From DTI   |   Ad
Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.
Use this link to see Nvidia Unchained right away!

Starpharma Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/5/2024Robert ThomasInsiderBuy300,000A$0.09A$27,900.00
10/23/2024Robert ThomasInsiderBuy200,000A$0.09A$18,600.00
9/13/2024Russell BasserInsiderBuy200,000A$0.09A$18,600.00
9/2/2024David McIntyreInsiderBuy405,886A$0.01A$4,058.86
6/28/2024Jeff DaviesInsiderBuy879,687A$0.09A$80,051.52
6/26/2024Robert ThomasInsiderBuy200,000A$0.09A$17,800.00
6/20/2024Robert ThomasInsiderBuy250,000A$0.09A$22,750.00
5/29/2024Robert ThomasInsiderBuy150,000A$0.12A$17,700.00
4/15/2024Robert ThomasInsiderBuy100,000A$0.13A$13,000.00
4/12/2024Russell BasserInsiderBuy71,428A$0.14A$9,999.92
4/10/2024Robert ThomasInsiderBuy250,000A$0.17A$43,500.00
10/31/2022Robert ThomasInsiderBuy50,000A$0.52A$26,000.00
9/12/2022Jacinth (Jackie) FairleyInsiderBuy30,000A$0.57A$17,190.00
See Full Table
This Bull Market Indicator called NVDA at $116
From WealthPress   |   Ad
Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…
All you have to do is follow this link here

SEC Filings (Institutional Ownership Changes) for Starpharma (ASX:SPL)

22.35% of Starpharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Starpharma logo
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers. In addition, the company's DEP radiotheranostics development pipeline includes DEP HER2-zirconium, a HER2-targeted radio diagnostic for HER2-positive cancers, such as breast and gastric cancer; and HER2-targeted DEP SN38 ADC, a targeted ADC therapeutic for the treatment of human ovarian cancer. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.
Read More on Starpharma

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

351,391 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

9.30%

Beta

0.77

Who are the company insiders with the largest holdings of Starpharma?

Starpharma's top insider investors include:
  1. David McIntyre (Insider)
  2. Jeff Davies (Insider)
  3. Robert Thomas (Insider)
  4. Russell Basser (Insider)
Learn More about top insider investors at Starpharma.
JD Vance Predicts: Wall Street vs. Trump & Your Money
From Priority Gold   |   Ad
Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.
Get your free guide NOW before it's too late.